BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Belbuca readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Belbuca\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05778591-9306@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Belbuca: Phase 2 readout est. (NCT05778591)
DESCRIPTION:Belbuca\, phase 2.\nStudy: Low-dose Buprenorphine as a Modulato
 r of Social Motivation in Schizophrenia\nEstimated primary completion: 1 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belbuca
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT057
 78591
URL:https://assetmemo.bio/drug/belbuca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799571-9306@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Belbuca: Phase 1 readout est. (NCT07799571)
DESCRIPTION:Belbuca\, phase 1.\nStudy: Buprenorphine for the Management of 
 Pain in Children With Sickle Cell Disease\nEstimated primary completion: O
 ctober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belbuca#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0779
 9571
URL:https://assetmemo.bio/drug/belbuca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
